Become A MemberEvent Registration
Close Menu
Chicago Innovation Award Winner


Winner in: 2015
Winning Product: HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase]
Winner Category: Chicago Innovation Award
Industry: Healthcare

Primary Immunodeficiency (PI) is a group of more than 200 rare, chronic disorders in which the body’s immune system does not function properly or is missing key parts. Managing the disease is a daily and lifelong challenge. People with PI receive antibody treatments to replace the missing parts of the immune system and help them fight infection, but the frequency of treatment through intravenous infusions or subcutaneous injections can be daunting. People with PI can feel limited by their disease and treatment regimens and many communicate a desire to travel without medical equipment, participate in a full day of activities without the need for rest, exercise without worry or simply to leave their house without fear of getting sick. At Baxalta, we put patients at the center of everything we do. We have made it not only our business but our passion to understand the journey of people with PI. Insights learned over years of close communication with people with PI, their families and health care professionals showed the need for a different treatment option that combined the at-home ease of fewer needle sticks and more time between treatments. It was with this relentless focus on patients that Baxalta designed and delivered HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] for the treatment of adults with PI.

Stay in the know on events &
news for Chicago innovators

Sign up to discover upcoming events and read the latest news about Chicago's innovators.

site by simple edge